BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.30) by 47.19 percent. This is a 46.67 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $2.000 million which beat the analyst consensus estimate of $700.000 thousand by 185.71 percent.